• Akebia Therapeutics held its annual shareholder meeting on June 17, 2026.
• Shareholders backed an amendment to increase authorized shares to 525 million, including common stock to 500 million; the amendment was filed June 18, 2026.
• Shareholders ratified Ernst & Young as independent auditor for the fiscal year ending Dec. 31, 2026.
• Shareholders endorsed holding future advisory votes on executive pay every year; the board indicated it intends to follow that schedule.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001517022-26-000043), on June 22, 2026, and is solely responsible for the information contained therein.